Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cellectar Biosciences, Inc. CLRB

Healthcare  —  Biotechnology
1.80 (0.28) (13.46%) as of 25 Sep
Market cap
$19.6M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Cellectar Biosciences, Inc. (CLRB) Business Profile

Updated before January 2025

Company Overview

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies. Founded in 2002 and headquartered in Florham Park, New Jersey, Cellectar leverages its proprietary phospholipid drug conjugate (PDC) platform to develop innovative treatments for cancer patients. The company’s leadership team includes experienced professionals in the biotechnology and pharmaceutical industries, with James Caruso serving as the President and Chief Executive Officer. Under Caruso’s guidance, Cellectar has advanced its pipeline of targeted therapies and strengthened its position in the oncology sector.

Core Business Segments

Cellectar Biosciences operates primarily in the oncology space, with its core business centered around the development of targeted cancer therapies. The company’s product portfolio is built on its proprietary PDC platform, which enables the selective delivery of therapeutic agents to cancer cells while sparing healthy tissues. Key products and services include:

  • CLR 131: Cellectar’s lead product candidate, CLR 131, is a small-molecule radiotherapeutic designed to treat a variety of cancers, including multiple myeloma and pediatric solid tumors. CLR 131 has shown promising results in clinical trials, demonstrating its potential to improve patient outcomes.

  • PDC Platform: The company’s proprietary PDC platform is a versatile technology that can be used to develop targeted therapies for a wide range of cancers. By conjugating therapeutic agents to phospholipid ethers, the platform enables selective delivery to cancer cells, reducing off-target effects and improving efficacy.

  • Pipeline Development: In addition to CLR 131, Cellectar is actively developing other PDC-based therapies for hematologic and solid tumors. These include preclinical and early-stage clinical candidates targeting unmet medical needs in oncology.

Business Model

Cellectar Biosciences operates as a research-driven organization, focusing on the development and commercialization of targeted cancer therapies. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. Key elements of its business model include:

  • Research and Development (R&D): Cellectar invests heavily in R&D to advance its pipeline of PDC-based therapies. The company collaborates with academic institutions, research organizations, and industry partners to accelerate the development of innovative treatments.

  • Strategic Partnerships: Cellectar seeks to establish partnerships with pharmaceutical companies to co-develop and commercialize its therapies. These collaborations provide access to additional resources and expertise, enabling the company to bring its products to market more efficiently.

  • Regulatory Approvals: The company’s ability to generate revenue depends on obtaining regulatory approvals for its product candidates. Cellectar works closely with regulatory agencies to ensure compliance with safety and efficacy standards.

Strategic Direction

Cellectar Biosciences is committed to advancing its mission of improving the lives of cancer patients through innovative therapies. The company’s strategic priorities include:

  • Pipeline Expansion: Cellectar aims to expand its pipeline of PDC-based therapies by advancing existing candidates and exploring new indications. The company is particularly focused on addressing unmet medical needs in oncology.

  • Global Market Penetration: Cellectar plans to expand its presence in international markets by pursuing regulatory approvals and establishing partnerships with global pharmaceutical companies.

  • Sustainability Goals: The company is dedicated to minimizing its environmental impact by adopting sustainable practices in its operations and supply chain.

  • Innovation and Technology: Cellectar continues to invest in its PDC platform to enhance its capabilities and develop next-generation therapies.

Competitive Landscape

Cellectar Biosciences operates in a highly competitive oncology market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Seagen Inc.: A leader in antibody-drug conjugates (ADCs), Seagen develops targeted therapies for cancer treatment.
  • Bluebird Bio: Focused on gene and cell therapies, Bluebird Bio develops innovative treatments for cancer and genetic diseases.
  • ImmunoGen, Inc.: Specializing in ADCs, ImmunoGen develops targeted therapies for hematologic malignancies and solid tumors.
  • Novartis AG: A global pharmaceutical company with a strong oncology portfolio, including targeted therapies and radiopharmaceuticals.

Cellectar differentiates itself through its proprietary PDC platform, which offers unique advantages in terms of selectivity and efficacy.

Risk Factors

Cellectar Biosciences faces several risks that could impact its business operations and financial performance, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for its product candidates could hinder the company’s ability to commercialize its therapies.
  • Market Dependence: The company’s success depends on the commercial viability of its product candidates, particularly CLR 131. Market acceptance and competition could affect sales.
  • Supply Chain Disruptions: Disruptions in the supply chain for raw materials and manufacturing processes could delay product development and commercialization.
  • Financial Risks: As a clinical-stage company, Cellectar relies on external funding to support its operations. Limited financial resources could constrain its ability to advance its pipeline.

Recent Developments

Cellectar Biosciences has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trial Updates: The company has reported positive interim results from its Phase 2 clinical trial of CLR 131 in patients with relapsed or refractory multiple myeloma. These results highlight the potential of CLR 131 to improve patient outcomes.
  • Partnerships and Collaborations: Cellectar has entered into strategic partnerships with academic institutions and research organizations to accelerate the development of its PDC-based therapies.
  • Corporate Initiatives: The company has implemented cost-saving measures and operational efficiencies to optimize its resources and extend its financial runway.

Investment Considerations

Investors considering Cellectar Biosciences should weigh the following strengths and risks:

Strengths:

  • Innovative Technology: The PDC platform offers a unique approach to targeted cancer therapy, with potential applications across multiple indications.
  • Promising Pipeline: CLR 131 and other PDC-based candidates have shown encouraging results in clinical trials, demonstrating their potential to address unmet medical needs.
  • Experienced Leadership: The company’s management team has a proven track record in the biotechnology and pharmaceutical industries.

Risks:

  • Clinical and Regulatory Uncertainty: The success of Cellectar’s product candidates depends on the outcomes of clinical trials and regulatory approvals.
  • Financial Constraints: As a clinical-stage company, Cellectar relies on external funding to support its operations. Limited financial resources could impact its ability to advance its pipeline.
  • Market Competition: The oncology market is highly competitive, with numerous companies developing targeted therapies.

Conclusion

Cellectar Biosciences, Inc. is a pioneering biopharmaceutical company dedicated to developing targeted cancer therapies. With its innovative PDC platform and promising pipeline, the company is well-positioned to address unmet medical needs in oncology. While challenges remain, including regulatory and financial risks, Cellectar’s strategic direction and commitment to innovation provide a strong foundation for future growth. As the company continues to advance its pipeline and expand its market presence, it has the potential to make a significant impact in the fight against cancer.